Bollard Group’s Quest Diagnostics DGX Stock Holding History

Bollard Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$1K	–	456
2023 Q2	$1K	Buy	+5	New	+$689	﹤0.01%	584

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bollard Group's DGX Position: Q3 2023 in Review

Bollard Group sold out of Quest Diagnostics (DGX) in Q3 2023, closing a stake of 5 shares — an estimated $1K sold.

Bollard Group first reported a position in DGX in Q2 2023 and held it in 1 quarter. The position peaked at $1K in Q2 2023. 794 funds tracked by Wall St. Rank hold DGX as of Q3 2023.

Bollard Group reported no remaining Quest Diagnostics position as of Q3 2023 after selling out during the quarter.
Bollard Group sold 5 Quest Diagnostics shares in Q3 2023, an estimated $1K.
Bollard Group first reported a position in Quest Diagnostics in Q2 2023 and held it in 1 quarter.
Bollard Group's Quest Diagnostics position peaked at $1K in Q2 2023.
794 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.

Based on Bollard Group's 13F filing for Q3 2023, filed 14 Nov 2023.